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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease that results in
telangiectasia of the sinonasal tract, gastro-intestinal tract as well as possible arteriovenous malformations of the
lung, liver and brain. One of the most common disease manifestations of HHT is epistaxis. Severe recurrent epistaxis
necessitating iron therapy and blood transfusion is often managed with septodermoplasty. Its initial description was
as an open surgical technique requiring nasal packing.
Case presentation: We describe a modified approach to septodermoplasty done completely endoscopically and
without nasal packing for a patient with severe epistaxis due to HHT.
Conclusion: The described technique modifications for the presented case allowed for same day discharge
following surgery, complete take of the skin graft and resultant epistaxis control that ended thepatient's transfusion
dependency. The merits of these modifications should be further evaluated in a clinical trial.
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Background
Hereditary hemorrhagic telangiectasia (HHT) is an auto-
somal dominant disease, which results in blood vessel
malformation most commonly within mucous membranes
and the skin. In the late 19th century Osler, Weber and
Rendu described a series of patients with a constellation
of symptoms including frequent epistaxis, recurrent
gastrointestinal bleeding, iron deficiency anemia and mul-
tiple telangiectasia on the vermillion border of the lips
and fingertips [1–3]. These patients were subsequently
recognized as a definite medical entity known as Osler
Weber Rendu syndrome, now otherwise known as HHT.
The common mucosal vascular malformation that occurs
in HHT, telangiectasia, often bleed spontaneously or with
minimal trauma. Although the initial clinical disease pres-
entation can vary, the most common symptom of patients
with HHT is recurrent epistaxis. Epistaxis is typically the
earliest sign of the disease while mucocutaneous and
gastrointestinal telangiectasia develop progressively with
age [4]. The average age of onset for epistaxis is 12 years of
age, with nearly 100 % of patients affected by epistaxis by
age 40 [5–7].
Treatment for HHT-related epistaxis is focused on the
reduction of the frequency and severity of bleeding. Mul-
tiple modalities have reportedly been used including oral
tranexamic acid [8], and topical estrogen-containing oint-
ment [9]. A relatively new modality of therapy has been
Bevacizumab, a monocolonal antibody inhibitor of vascular
endothelial growth factor (VEGF) [10]. Previous studies
have demonstrated that intransal administration of Bevaci-
zumab can significantly diminish the frequency and sever-
ity of epistaxis in this patient population [11–13].
Although strict medical management can reduce symp-
tom severity, many patients are refractory to pure medical
measures and require oral iron supplementation and/or
regular blood transfusions. For patients who have failed
medical therapy surgical options, including laser
coagulation or septodermoplasty, are often employed.
Laser ablation however usually requires multiple sessions
and is less effective for lesions greater than 2 mm in diam-
eter [14]. Currently, the gold standard for severe recurrent
epistaxis for patients with HHT is septodermoplasty. This
technique was initially described in 1962 by Saunders et al
[15] and it involves the removal of affected nasal epithe-
lium and its replacement with a split-thickness skin graft
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(STSG). A variation of this technique for severe epistaxis
management, known as Young’s procedure [16] involves a
septodermoplasty with complete nasal closure.
The objective of this report is to use an illustrative case
to describe technique alterations for septodermoplasty
that may improve patient care by providing an alternative
for improved surgeon visualization, for rapid hemostasis
and for secure STSG placement without nasal packing.
Case presentation
A 64 year old female known for HHT is referred to our
clinic for recurrent epistaxis for nearly 50 years. She has
had recurrent symptoms since the age of 16 when her con-
dition was diagnosed. All three of her siblings also were di-
agnosed with HHT and her mother passed away from an
intracranial hemorrhage. Eight years prior to presentation
she had undergone a left-sided septodermoplasty via a lat-
eral rhinotomy approach. This operation had significantly
reduced the frequency of her symptoms and for several
years her epistaxis was under control with the use of low
dose thalidomide. However, she was referred to our clinic
due to increased epistaxis severity and frequency over the
prior 12 months necessitating more frequent transfusions.
At the time of consultation the patient was concerned
about daily severe left sided epistaxis despite several
months use of topical bevacizumab and oral tranexamic
acid. She required intravenous iron and blood transfusions
every two months. Her baseline hemoglobin at the time of
our consultation was 75 g/L (normal = 120 – 160 g/L). Her
HHT epistaxis severity score [17] was severe (normalized
score 9.49). On examination, she had multiple telangiecta-
sia on her fingers, face, lips and palate. Her endoscopic
examination revealed bilateral telangiectasia along the nasal
septum. There was extensive crusting along the entire left
nasal cavity with which any manipulation resulted in imme-
diate profuse epistaxis. Given the severity of the patient’s
epistaxis despite medical therapy, she was offered endo-
scopic left-sided septodermoplasty. The surgical goals were
to improve her quality of life by reducing the number and
severity of epistaxis episodes while diminishing the need for
blood transfusions. The patient was content with the treat-
ment plan and agreed to undergo surgical intervention.
Operative procedure
The endoscopic procedure was performed under general
anesthesia with endotracheal intubation. The nasal cavity
was prepared by inserting pledgets soaked in topical adren-
aline (1:1000) placed in both nostrils for decongestion.
Using a zero degree endoscope the residual STSG and mu-
cosa of the left septum was dissected in a supraperichon-
drial plane that resulted in the expected significant diffuse
hemorrhage. Immediate hemostasis was attained using a
topical gelatin-thrombin matrix, Floseal (FloSeal Hemostatic
Matrix; Baxter Healthcare Corporation, Deerfield, IL, USA)
(Fig. 1). The mucosal defect (Fig. 2) measured approxi-
mately 3 cm in anterior-posterior dimension.
A 4 x 2 cm split thickness skin graft was harvested from
the right thigh, pie-crusted with a 15 blade and then placed
endoscopically along the length of the septal defect. As seen
in Fig. 3, the graft was placed with an overlap of the mucosa
of the nasal floor and the residual superior septal mucosa.
Finally, 2 mL of fibrin sealant (TISSEEL fibrin sealant, Baxter
Healthcare Corporation, Deerfield, IL, USA) was then
applied first to the edges then central portion of the STSG
(Fig. 4). Packing was not used post-operatively and the
patient was discharged home on the same day of surgery.
Post-operative course
Clinical follow-up two weeks after surgery (Fig. 5)
showed that the entire graft had taken and the left-sided
epistaxis had dramatically diminished. The patient was
very content with the results of the procedure. At
6 months follow-up, her baseline hemoglobin had
Fig. 1 Left septodermoplasty demonstrating application of Floseal
for hemostasis
Fig. 2 Left septodermoplasty demonstrating the septal mucosal defect
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improved to 102 g/L and she was requiring transfusions
every 4 months with her hematologist’s intent to stop
the transfusions if her hemoglobin remained greater
than 100 g/L. Her epistaxis severity score at 6 month
follow up was mild (normalized score 3.05).
Discussion
The frequency and duration of epistaxis is a major deter-
minant of quality of life in patients with HHT [18–21].
Septodermoplasty has been shown to adequately decrease
symptom severity in 80-100 % of patients up to 6 months
post-operatively [22–24]. Many variations of a septodermo-
plasty have previously been described. Saunders originally
described using a lateral rhinotomy approach, which
continues to be the most common approach to septoder-
moplasty. Other variations have included closure of nasal
valve (Young’s procedure) [16] as well as buccal mucosal
grafts instead of a STSG [25].
Although different approaches have previously been
reported we submit that the technique described herein
provides several advantages. Firstly, under endoscopic guid-
ance optimal visualization for the entire surgical field is
achieved. Ultimately, this allows for increased precision
when excising the mucosa as well as ensuring accurate
placement of the STSG. Second hemostasis is readily and
rapidly achieved with the use of a topical gelatin-thrombin
matrix following excision of the nasal septal mucosa. A dry
surgical field is imperative when placing the STSG as this
diminishes the likelihood of graft hematoma and subse-
quent failure of the graft [26–28]. Finally, by using a fibrin
tissue glue, nasal packing is not required to secure the graft,
arrest bleeding, nor to prevent post-operative hematoma.
Further, nasal packing can often be a significant source of
pain and morbidity in the immediate post-operative period
[29, 30]. The colonisation of nasal packing by Staphylococcus
aureus could also result in STSG loss due to its subsequent
infection and disrupted healing [29–32].
Conclusion
Endoscopic septodermoplasty is a minimally invasive
method of performing this classically open surgical pro-
cedure. Minimizing blood loss in this chronically anemic
patient population is imperative, the use of a topical
gelatin-thrombin matrix allows for rapid hemostasis for
a sizeable surgical wound. This also provides a dry surgi-
cal bed to receive the skin graft and the use of fibrin
tissue glue is a packing-free method of securing the skin
graft that decreases postoperative patient discomfort as
well as decreasing the chances of skin graft loss due to
infection from nasal packing bacterial colonisation. We
suggest that future studies should compare long-term
efficacy of this technique and its cost-benefit with open
septodermoplasty.
Fig. 3 Left septodermoplasty demonstrating endoscopic STSG
placement
Fig. 4 Endoscopic application of TISSEEL sealant over the STSG
Fig. 5 Endoscopic image at two weeks follow-up post left sided
septodermoplasty
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